糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

Diabetes Care：终末糖基化产物（AGE）水平升高与视网膜病变进展相关

2012-04-25 高晓方译 医学论坛网

糖尿病视网膜病变终末糖基化产物
关注

　　美国学者的一项研究表明，在1型糖尿病患者中，免疫复合物中（IC）中终末糖基化产物（AGE）-LDL和氧化LDL（oxLDL）水平升高与晚期视网膜病变进展风险升高相关。论文于2011年4月17日在线发表于《糖尿病护理》（Diabetes Care）杂志。 　　此项研究共纳入517例糖尿病患者，并测定了IC中的AGE-LDL和oxLDL水平。利用立体眼底摄像评估视网膜病变。利用Cox比

　　美国学者的一项研究表明，在1型糖尿病患者中，免疫复合物中（IC）中终末糖基化产物（AGE）-LDL和氧化LDL（oxLDL）水平升高与晚期视网膜病变进展风险升高相关。论文于2011年4月17日在线发表于《糖尿病护理》（Diabetes Care）杂志。

　　此项研究共纳入517例糖尿病患者，并测定了IC中的AGE-LDL和oxLDL水平。利用立体眼底摄像评估视网膜病变。利用Cox比例风险模型评估AGE-LDL-IC和oxLDL-IC对视网膜病变进展的影响。随访时间超过16年。

　　结果显示，在未校正模型中，基线AGE-LDL-IC和oxLDL-IC高水平可显著预测糖尿病视网膜病变的进展转归。对治疗组、视网膜病变人群、1型糖尿病持续时间以及基线白蛋白排泄率（AER）、糖化血红蛋白和早期糖尿病视网膜病变治疗研究（ETDRS）评分等研究设计变量进行校正后，AGE-LDL-IC和oxLDL-IC水平每升高一个标准差（SD）与增生型糖尿病视网膜病变（PDR）形成风险升高47%和45%相关，并且均与严重非增生型视网膜病变进展风险升高37%相关。由于初级和次级人群存在结果差异，因此依据视网膜病变人群进行分层分析。对于AGE-LDL-IC，在初级人群中进展至PDR的危险比为2.38，并且在次级人群中减弱。oxLDL-IC的结果与之相似。

　　链接：　　

Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G; the DCCT/EDIC Study Group.High Concentrations of AGE-LDL and Oxidized LDL in Circulating Immune Complexes Are Associated With Progression of Retinopathy in Type 1 Diabetes.Diabetes Care. 2012 Apr 17.
 

 



    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-07-11 ms5439512287675881

    #BET#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-06-01 ms9608593228839890

    #DIA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-05-17 木头人513

    #Diabetes#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 zutt

    #视网膜#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 lfyang

    #糖基化#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 zhanfl

    #视网膜病变#

    0

相关资讯

PNAS：德国科学家揭示甘草具有抗糖尿病的作用

甘草是传统中医中的一种很重要的草本植物，其使用种类记载已久。数千年来，中国医疗家们使用甘草来治疗多种疾病，上至喉咙痛，下至溃疡，而且还被当做养心和补脾的滋补品。其根也被用于药用上。近年来自世界的研究机构及许多科学家对于甘草研究均表现出浓厚的兴趣。有研究证实甘草根作为甘草果糖原材料，可舒缓减轻胃及呼吸道疾患。 近日来自德国柏林马克斯-普朗克分子遗传学研究所的研究人员发现甘草根（liquorice

异麦芽酮糖取代蔗糖对2型糖尿病血糖控制无影响

　　德国一项研究表明，异麦芽酮糖对日常生活状态下2型糖尿病患者的血糖控制（以糖化血红蛋白评估）无影响，但是和低水平的甘油三酯有关联。该研究4月9日在线发表于《糖尿病护理》（Diabetes Care）杂志。研究纳入110例2型糖尿病患者并随机分为两组，作为饮食习惯，每日食用含50 g异麦芽酮糖或蔗糖的食品。对101例患者接受分析的结果显示，食用异麦芽酮糖食品并未显著影响12周的

改善2型糖尿病肥胖患者胰岛素抵抗，减肥手术优于艾塞那肽

　　中国医科大学附属盛京医院普外科一项研究显示，对于2型糖尿病肥胖患者，胃旁路手术在控制体重和改善胰岛素抵抗等方面均优于艾塞那肽治疗。研究于3月23日在线发表于《肥胖外科学》（Obes Surg）。 　　研究纳入该院2009年1月～2010年1月接受减肥手术或艾塞那肽治疗的2型糖尿病肥胖患者，收集的数据包括体重改变、血糖、胰岛素变化、HbA1C以及患者的主观评分。结果显示，相比艾塞那肽

肥胖糖尿病患者减肥手术表现优于药物治疗

　　《外科学文献》（Arch Surg）4月16日在线发布的一项研究表明，在病态肥胖的糖尿病患者中，腹腔镜胃束带减肥术较药物治疗对控制糖尿病更有效。 　　研究者对60例患者随访了18个月，其中半数进行手术，其余皆是最佳药物治疗。治疗前，患者的平均体质指数（BMI）约为40。第18个月，手术患者体质减轻较药物治疗患者多，最终BMI分别为28和40。80%的手术患者糖尿病痊愈，而药物

中国高血压患者合并糖尿病较常见

　　我国北京安贞医院研究人员在2012年世界心脏病学大会（4月18～21日，阿联酋迪拜）上公布的一项研究显示：虽然我国高血压患者的糖尿病流行率较高，但是，即便他们正在接受糖尿病治疗，其糖尿病知晓率仍很低。此外，高血压合并糖尿病的患者的降血糖治疗率和血糖达标率均很低。研究人员认为：在接受治疗的中国高血压患者中，强调血糖检测的重要性和提高护理质量很重要。 　　此项横断面调查样本来自2009年中

刘学波：糖尿病合并冠心病 介入治疗重在管理

       导语：糖尿病与心血管病之间存在着密切的内在联系，二者互为高危人群。2001年美国国家胆固醇教育计划成人治疗指南Ⅲ（NCEP-ATP Ⅲ）指出：糖尿病是冠心病的等危症。2007年，美国心脏病学院甚至发出了“糖尿病就是心血管病”的呼声。提高对糖尿病患者冠状动脉病变和介入治疗的认识，以及加强经皮冠状动脉介入治疗（PCI）术后对血糖等危险因素的管理，对